Histologic Validation of Myocardial Fibrosis Measured by T1 Mapping: a Systematic Review and Meta-analysis

Overview

Journal J Cardiovasc Magn Reson

Publisher Elsevier

Specialties Cardiology & Vascular Diseases
Radiology

Date 2016 Dec 14

PMID 27955698

Citations 75

Authors

Kai-Yue Diao

Zhi-Gang Yang

Hua-Yan Xu

Xi Liu

Qin Zhang

Ke Shi

Li Jiang

Lin-Jun Xie

Ling-Yi Wen

Ying-Kun Guo

Affiliations

Soon will be listed here.

Abstract

Background: Myocardial fibrosis is being increasingly recognised as a common final pathway of a wide range of diseases. Thus, the development of an accurate and convenient method to evaluate myocardial fibrosis is of major importance. Although T1 mapping is a potential alternative for myocardial biopsy, validation studies are limited to small numbers and vary regarding technical facets, and include only a restricted number of disease. A systematic review and meta-analysis was conducted to objectively and comprehensively evaluate the performance of T1 mapping on the quantification of myocardial fibrosis using cardiovascular magnetic resonance (CMR).

Methods: PubMed, EMBASE and the Cochrane Library databases were searched for studies applying T1 mapping to measure myocardial fibrosis and that validated the results via histological analysis. A pooled correlation coefficient between the CMR and histology measurements was used to evaluate the performance of the T1 mapping.

Results: A total of 15 studies, including 308 patients who had CMR and myocardial biopsy were included and the pooled correlation coefficient between ECV measured by T1 mapping and biopsy for the selected studies was 0.884 (95% CI: 0.854, 0.914) and was not notably heterogeneous chi-squared = 7.44; P = 0.489 for the Q test and I^2 = 0.00%).

Conclusions: The quantitative measurement of myocardial fibrosis via T1 mapping is associated with a favourable overall correlation with the myocardial biopsy measurements. Further studies are required to determine the calibration of the T1 mapping results for the biopsy findings of different cardiomyopathies.

Citing Articles

Extracellular volume fraction and native T1 mapping in diabetic cardiomyopathy: a comprehensive meta-analysis.

Marey A, Alabdullah A, Ghorab H, Ali F, Abdulla J, Narang A BMC Cardiovasc Disord. 2025; 25(1):70.

PMID: 39893360 PMC: 11786336. DOI: 10.1186/s12872-025-04496-z.

Feasibility of iodine concentration parameter and extracellular volume fraction derived from dual-energy CT for distinguishing type I and type II epithelial ovarian carcinoma.

Song Q, Li Y, Wu T, Hu W, Liu Y, Liu A Abdom Radiol (NY). 2024; .

PMID: 39665991 DOI: 10.1007/s00261-024-04752-4.

Cardiovascular magnetic resonance reveals myocardial involvement in patients with active stage of inflammatory bowel disease.

Fenski M, Abazi E, Groschel J, Hadler T, Kappelmayer D, Kolligs F Clin Res Cardiol. 2024; .

PMID: 39102000 DOI: 10.1007/s00392-024-02503-5.

Assessing Left Ventricular Pathology in Patients with Ebstein Anomaly Using Cardiovascular Magnetic Resonance: Looking Past the Right Heart.

Gupta A, Da Silva L, Wang L, Diaz-Castrillon C, Dobson C, da Silva J Pediatr Cardiol. 2024; .

PMID: 39033244 DOI: 10.1007/s00246-024-03585-8.

Unveiling myocardial microstructure shifts: exploring the impact of diabetes in stable CAD patients through CMR T1 mapping.

Boros G, Hueb W, Rezende P, Rochitte C, Nomura C, Lima E Diabetol Metab Syndr. 2024; 16(1):156.

PMID: 38982515 PMC: 11232262. DOI: 10.1186/s13098-024-01395-9.

References

OHanlon R, Grasso A, Roughton M, Moon J, Clark S, Wage R . Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010; 56(11):867-74. DOI: 10.1016/j.jacc.2010.05.010. View

Sibley C, Noureldin R, Gai N, Nacif M, Liu S, Turkbey E . T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012; 265(3):724-32. PMC: 3504318. DOI: 10.1148/radiol.12112721. View

Iles L, Ellims A, Llewellyn H, Hare J, Kaye D, McLean C . Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2014; 16(1):14-22. DOI: 10.1093/ehjci/jeu182. View

Moon J, Messroghli D, Kellman P, Piechnik S, Robson M, Ugander M . Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013; 15:92. PMC: 3854458. DOI: 10.1186/1532-429X-15-92. View

Fontana M, White S, Banypersad S, Sado D, Maestrini V, Flett A . Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2013; 14:88. PMC: 3552758. DOI: 10.1186/1532-429X-14-88. View

Sharma P, Socolow J, Patel S, Pettigrew R, Oshinski J . Effect of Gd-DTPA-BMA on blood and myocardial T1 at 1.5T and 3T in humans. J Magn Reson Imaging. 2006; 23(3):323-30. PMC: 7166832. DOI: 10.1002/jmri.20504. View

De Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J . Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson. 2015; 17:48. PMC: 4464705. DOI: 10.1186/s12968-015-0150-0. View

Azevedo C, Nigri M, Higuchi M, Pomerantzeff P, Spina G, Sampaio R . Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010; 56(4):278-87. DOI: 10.1016/j.jacc.2009.12.074. View

Flett A, Hayward M, Ashworth M, Hansen M, Taylor A, Elliott P . Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010; 122(2):138-44. DOI: 10.1161/CIRCULATIONAHA.109.930636. View

10.

Raman F, Kawel-Boehm N, Gai N, Freed M, Han J, Liu C . Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners. J Cardiovasc Magn Reson. 2013; 15:64. PMC: 3733695. DOI: 10.1186/1532-429X-15-64. View

11.

Mewton N, Liu C, Croisille P, Bluemke D, Lima J . Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011; 57(8):891-903. PMC: 3081658. DOI: 10.1016/j.jacc.2010.11.013. View

12.

Burt J, Zimmerman S, Kamel I, Halushka M, Bluemke D . Myocardial T1 mapping: techniques and potential applications. Radiographics. 2014; 34(2):377-95. PMC: 4358720. DOI: 10.1148/rg.342125121. View

13.

Roujol S, Weingartner S, Foppa M, Chow K, Kawaji K, Ngo L . Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology. 2014; 272(3):683-9. PMC: 4263641. DOI: 10.1148/radiol.14140296. View

14.

Cooper L, Baughman K, Feldman A, Frustaci A, Jessup M, Kuhl U . The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure.... Eur Heart J. 2007; 28(24):3076-93. DOI: 10.1093/eurheartj/ehm456. View

15.

Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo J . Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000; 101(14):1729-35. DOI: 10.1161/01.cir.101.14.1729. View

16.

Mascherbauer J, Marzluf B, Tufaro C, Pfaffenberger S, Graf A, Wexberg P . Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2013; 6(6):1056-65. DOI: 10.1161/CIRCIMAGING.113.000633. View

17.

Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta S . Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008; 52(19):1574-80. DOI: 10.1016/j.jacc.2008.06.049. View

18.

Whiting P, Rutjes A, Westwood M, Mallett S, Deeks J, Reitsma J . QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155(8):529-36. DOI: 10.7326/0003-4819-155-8-201110180-00009. View

19.

Lee J, Liu S, Nacif M, Ugander M, Han J, Kawel N . Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson. 2011; 13:75. PMC: 3269374. DOI: 10.1186/1532-429X-13-75. View

20.

Karamitsos T, Francis J, Myerson S, Selvanayagam J, Neubauer S . The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009; 54(15):1407-24. DOI: 10.1016/j.jacc.2009.04.094. View